Literature DB >> 16307506

Development of effective therapies against West Nile virus infection.

Michael S Diamond1.   

Abstract

Since its entry into North America in 1999, West Nile virus has spread throughout the USA and Canada, and now annually causes a clinical spectrum of human disease ranging from a self-limiting acute febrile illness to potentially lethal encephalitis. Although no therapy is currently approved for use in humans, several strategies are being pursued to develop effective prophylaxis and treatments. This review describes the epidemiology, clinical presentation and pathogenesis of West Nile virus infection, and highlights recent progress towards an effective therapy.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16307506     DOI： 10.1586/14787210.3.6.931

Source DB:  PubMed          Journal:  Expert Rev Anti Infect Ther        ISSN： 1478-7210            Impact factor:   5.091


  11 in total

1.  Chimeric vaccine composed of viral peptide and mammalian heat-shock protein 60 peptide protects against West Nile virus challenge.

Authors:  Orly Gershoni-Yahalom; Shimon Landes; Smadar Kleiman-Shoval; David Ben-Nathan; Michal Kam; Bat-El Lachmi; Yevgeny Khinich; Michael Simanov; Itzhak Samina; Anat Eitan; Irun R Cohen; Bracha Rager-Zisman; Angel Porgador
Journal:  Immunology       Date:  2010-03-16       Impact factor: 7.397

2.  Anti-inflammatory activity of intravenous immunoglobulins protects against West Nile virus encephalitis.

Authors:  Ruchi Srivastava; Chandran Ramakrishna; Edouard Cantin
Journal:  J Gen Virol       Date:  2015-02-09       Impact factor: 3.891

Review 3.  Risk factors for West Nile virus infection and disease in populations and individuals.

Authors:  Ruth R Montgomery; Kristy O Murray
Journal:  Expert Rev Anti Infect Ther       Date:  2015-01-30       Impact factor: 5.091

4.  Gamma interferon plays a crucial early antiviral role in protection against West Nile virus infection.

Authors:  Bimmi Shrestha; Tian Wang; Melanie A Samuel; Kevin Whitby; Joe Craft; Erol Fikrig; Michael S Diamond
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

Review 5.  West Nile Virus: biology, transmission, and human infection.

Authors:  Tonya M Colpitts; Michael J Conway; Ruth R Montgomery; Erol Fikrig
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

6.  Defining the levels of secreted non-structural protein NS1 after West Nile virus infection in cell culture and mice.

Authors:  Kyung Min Chung; Michael S Diamond
Journal:  J Med Virol       Date:  2008-03       Impact factor: 2.327

7.  The relative contribution of antibody and CD8+ T cells to vaccine immunity against West Nile encephalitis virus.

Authors:  Bimmi Shrestha; Terry Ng; Hsien-Jue Chu; Michelle Noll; Michael S Diamond
Journal:  Vaccine       Date:  2008-02-20       Impact factor: 3.641

8.  Tumor necrosis factor alpha protects against lethal West Nile virus infection by promoting trafficking of mononuclear leukocytes into the central nervous system.

Authors:  Bimmi Shrestha; Bo Zhang; Whitney E Purtha; Robyn S Klein; Michael S Diamond
Journal:  J Virol       Date:  2008-07-16       Impact factor: 5.103

9.  Key role of T cell defects in age-related vulnerability to West Nile virus.

Authors:  James D Brien; Jennifer L Uhrlaub; Alec Hirsch; Clayton A Wiley; Janko Nikolich-Zugich
Journal:  J Exp Med       Date:  2009-11-09       Impact factor: 14.307

10.  Using high titer West Nile intravenous immunoglobulin from selected Israeli donors for treatment of West Nile virus infection.

Authors:  David Ben-Nathan; Orly Gershoni-Yahalom; Itzchak Samina; Yevgeny Khinich; Israel Nur; Orgad Laub; Ahuva Gottreich; Michael Simanov; Angel Porgador; Bracha Rager-Zisman; Nadav Orr
Journal:  BMC Infect Dis       Date:  2009-02-17       Impact factor: 3.090
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.